743 related articles for article (PubMed ID: 29867227)
1. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.
Zacharakis N; Chinnasamy H; Black M; Xu H; Lu YC; Zheng Z; Pasetto A; Langhan M; Shelton T; Prickett T; Gartner J; Jia L; Trebska-McGowan K; Somerville RP; Robbins PF; Rosenberg SA; Goff SL; Feldman SA
Nat Med; 2018 Jun; 24(6):724-730. PubMed ID: 29867227
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
Zacharakis N; Huq LM; Seitter SJ; Kim SP; Gartner JJ; Sindiri S; Hill VK; Li YF; Paria BC; Ray S; Gasmi B; Lee CC; Prickett TD; Parkhurst MR; Robbins PF; Langhan MM; Shelton TE; Parikh AY; Levi ST; Hernandez JM; Hoang CD; Sherry RM; Yang JC; Feldman SA; Goff SL; Rosenberg SA
J Clin Oncol; 2022 Jun; 40(16):1741-1754. PubMed ID: 35104158
[TBL] [Abstract][Full Text] [Related]
3. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
Zhou J; Dudley ME; Rosenberg SA; Robbins PF
J Immunother; 2005; 28(1):53-62. PubMed ID: 15614045
[TBL] [Abstract][Full Text] [Related]
4. Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
Rosenberg SA
Nat Rev Clin Oncol; 2011 Aug; 8(10):577-85. PubMed ID: 21808266
[TBL] [Abstract][Full Text] [Related]
5. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
6. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.
Goff SL; Dudley ME; Citrin DE; Somerville RP; Wunderlich JR; Danforth DN; Zlott DA; Yang JC; Sherry RM; Kammula US; Klebanoff CA; Hughes MS; Restifo NP; Langhan MM; Shelton TE; Lu L; Kwong ML; Ilyas S; Klemen ND; Payabyab EC; Morton KE; Toomey MA; Steinberg SM; White DE; Rosenberg SA
J Clin Oncol; 2016 Jul; 34(20):2389-97. PubMed ID: 27217459
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
8. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
Rosenberg SA
Annu Rev Med; 1996; 47():481-91. PubMed ID: 8712798
[TBL] [Abstract][Full Text] [Related]
9. Combined immune checkpoint blockade as a therapeutic strategy for
Nolan E; Savas P; Policheni AN; Darcy PK; Vaillant F; Mintoff CP; Dushyanthen S; Mansour M; Pang JB; Fox SB; ; Perou CM; Visvader JE; Gray DHD; Loi S; Lindeman GJ
Sci Transl Med; 2017 Jun; 9(393):. PubMed ID: 28592566
[TBL] [Abstract][Full Text] [Related]
10. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
11. Immune characterization of breast cancer metastases: prognostic implications.
Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer.
Karbach J; Kiselicki D; Brand K; Wahle C; Sinelnikov E; Gustavus D; Hoffmeister H; Prisack HB; Atmaca A; Jäger E
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36627144
[TBL] [Abstract][Full Text] [Related]
13. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma.
Veatch JR; Lee SM; Fitzgibbon M; Chow IT; Jesernig B; Schmitt T; Kong YY; Kargl J; Houghton AM; Thompson JA; McIntosh M; Kwok WW; Riddell SR
J Clin Invest; 2018 Apr; 128(4):1563-1568. PubMed ID: 29360643
[TBL] [Abstract][Full Text] [Related]
16. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.
Montagna E; Vingiani A; Maisonneuve P; Cancello G; Contaldo F; Pruneri G; Colleoni M
Breast; 2017 Aug; 34():83-88. PubMed ID: 28544923
[TBL] [Abstract][Full Text] [Related]
17. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
[TBL] [Abstract][Full Text] [Related]
18. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
19. Adoptive T-Cell Therapy for Cancer.
Yang JC; Rosenberg SA
Adv Immunol; 2016; 130():279-94. PubMed ID: 26923004
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Dudley ME; Wunderlich JR; Yang JC; Sherry RM; Topalian SL; Restifo NP; Royal RE; Kammula U; White DE; Mavroukakis SA; Rogers LJ; Gracia GJ; Jones SA; Mangiameli DP; Pelletier MM; Gea-Banacloche J; Robinson MR; Berman DM; Filie AC; Abati A; Rosenberg SA
J Clin Oncol; 2005 Apr; 23(10):2346-57. PubMed ID: 15800326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]